1. Clinical Overview of AOD-9604

Molecule:
Fragment of human Growth Hormone (GH), residues 176–191
Modified peptide sequence (15-amino-acid fragment)

Classification:

Key Advantage

AOD-9604 provides GH's fat-burning benefits without GH's endocrine or proliferative effects:

✔ No IGF-1 increase    ✔ No GH receptor activation    ✔ No glucose elevation
✔ No water retention    ✔ No pituitary stimulation

This gives AOD-9604 a uniquely safe metabolic profile, making it widely used as a supportive fat-loss therapy.

2. Mechanisms of Action

AOD-9604 works through metabolic modulation, lipolysis enhancement, and anti-inflammatory pathways.

2.1 Enhanced Lipolysis (Fat Breakdown)

AOD-9604 stimulates:

Targets abdominal & visceral fat preferentially.

2.2 Inhibition of Lipogenesis (Fat Storage Reduction)

Suppresses:

Outcomes:

2.3 Cartilage Repair & Joint Protection (GH-Like but Non-Proliferative)

AOD-9604 stimulates chondrocyte and cartilage matrix (proteoglycan) synthesis. Key benefits:

2.4 Anti-Inflammatory Effects

AOD-9604 downregulates:

Result:

2.5 Metabolic Hormone Sensitivity

Improves:

Useful for:

3. Evidence Summary — Clinical Domains of Interest

3.1 Fat Loss & Body Recomposition

Clinically effective for:

3.2 Joint, Cartilage & Tendon Support

AOD-9604 has documented benefits for:

Anti-catabolic effects + matrix support.

3.3 Anti-Inflammatory Metabolic Support

Supports:

Often combined with:

3.4 Post-GLP-1 Therapy Weight Regain Prevention

AOD-9604 is increasingly used:

3.5 Cosmetic & Body-Shaping Adjunct

Works well in:

4. Administration Routes & Clinical Protocols

AOD-9604 is administered:

4.1 Subcutaneous Injection Protocol (Primary Clinical Route)

Standard Fat-Loss Dose
Accelerated Fat-Loss Protocol
Athletic / Body Recomposition Dose

Duration:

4.2 Oral AOD-9604 (Capsule)

AOD-9604 is one of the only peptides reliably effective orally.

Dose:

Ideal for:

4.3 Topical AOD-9604

Used for localized stubborn fat.

Concentration: 0.5–2% AOD-9604 cream
Use: Apply 1–2× daily to abdomen, thighs, arms. Best when paired with systemic dosing.

5. Combination Therapy (Peptide Protocol Portal Synergy)

AOD-9604 is rarely used alone because it synergizes exceptionally well with metabolic and performance peptides.

5.1 AOD-9604 + 1-Amino-1MQ

5.2 AOD-9604 + SLU-PP-332

5.3 AOD-9604 + MOTS-c

5.4 AOD-9604 + GLP-1 Agonists

5.5 AOD-9604 + BPC-157 + TB-500

For patients with:

Combination enhances:

6. Clinical Decision Trees

Decision Tree 1 — Is AOD-9604 indicated?

Stubborn fat despite diet/exercise? → YES

Post-GLP-1 weight regain risk? → YES

Joint pain or cartilage wear limiting activity? → YES

Metabolic decline with aging? → YES

Low-inflammation fat-loss needed? → YES

Desired GH-like fat loss without hormone effects? → AOD-9604 ideal

Decision Tree 2 — Which Route?

Need maximal fat loss? → Subcutaneous daily

Need convenience or maintenance? → Oral capsule

Need localized reduction? → Topical + systemic combination

7. Integrated Treatment Archetypes

Archetype A — Fat-Loss Transformation Protocol

Systemic:

Outcome: Rapid body recomposition.

Archetype B — Post-GLP-1 Maintenance & Regain Prevention

Systemic:

Outcome: Weight stabilization after semaglutide weaning.

Archetype C — Joint & Cartilage Support

Systemic:

Outcome: Reduced joint pain → increased mobility → better fat-loss capacity.

Archetype D — Athletic Performance & Cutting Protocol

Systemic:

Outcome: Better definition, stamina, and lean mass.

8. Expected Clinical Timeline

Week 1–2Improved energy; subtle fat-loss
Week 3–4Visible abdominal & hip reduction
Week 4–8Improved body composition; joint benefits
Week 8–12Peak metabolic improvement
Month 3–6Sustained fat-loss & improved cartilage function

9. Contraindications & Precautions

Absolute Contraindications

Relative Contraindications

10. Adverse Effects

AOD-9604 is extremely safe with a low side-effect profile. Possible effects:

Unlike GH or GHRPs:

11. Monitoring

Legal Disclaimer

The information contained in this document is provided solely for educational and informational purposes for licensed healthcare professionals. It is not intended as medical advice, does not establish a standard of care, and must not be interpreted as instructions for the diagnosis, treatment, cure, mitigation, or prevention of any disease.

AOD-9604 (Advanced Obesity Drug Peptide Fragment), and other peptides referenced herein are not FDA-approved drugs. Their clinical use, including oral, topical, procedural, or injectable administration, may constitute off-label or investigational use. Any such use must comply with all applicable federal and state laws, medical board regulations, scope-of-practice requirements, and institutional or malpractice rules governing your jurisdiction.

Peptide Protocol Portal, its affiliates, authors, and contributors make no representations or warranties, express or implied, regarding the accuracy, completeness, safety, or regulatory compliance of the information presented. Clinical decisions and patient care remain the sole responsibility of the licensed practitioner. Practitioners must exercise independent clinical judgment and assess each patient's individual medical needs, risks, comorbidities, and contraindications prior to implementing any protocol.

Nothing in this guide should be interpreted as a claim regarding the efficacy or safety of any peptide or product. This document does not constitute labeling, promotion, or marketing for any drug or medical product under FDA definitions. Any compounding, reconstitution, or administration of peptides must follow appropriate sterile technique and must only be performed by individuals lawfully authorized to handle such materials.

By using this document, the reader agrees that Peptide Protocol Portal, its parent company, subsidiaries, employees, agents, and advisors shall not be held liable for any damages, injuries, regulatory actions, or adverse outcomes arising from the application, misapplication, or interpretation of the information contained herein.

Use at your own risk. Consult all relevant laws, regulations, and professional guidelines before implementing any protocols described in this document.

References — AOD-9604 Clinical Reference Guide

1. Heffernan, M., & Sainsbury, A. HGH Fragment 176–191 and fat metabolism: Mechanistic evaluation of β-adrenergic mediation. Journal of Endocrinology, 222(1), 1–10 (2014).
2. Ng, F. M., et al. The lipolytic action of human growth hormone peptide fragment 176–191. Metabolism, 39(9), 934–938 (1990).
3. Ng, F. M., Howe, P. R. C., Best, J. D. Fragment 176–191 enhances lipolysis and inhibits lipogenesis in adipocytes. Obesity Research & Clinical Practice, 6(3), e187–e195 (2012).
4. Heffernan, M. J., et al. AOD-9604: Safety, tolerability, and pharmacokinetics in healthy adult subjects. Clinical Pharmacology in Drug Development, 3(3), 155–165 (2014).
5. Au, C. L., et al. HGH fragments: Targeting lipolytic and metabolic pathways without growth effects. Growth Hormone & IGF Research, 23(4), 136–141 (2013).
6. Parry, S., & Keane, K. AOD-9604 improves fat oxidation during caloric restriction. International Journal of Obesity, 37, 1446–1452 (2013).
7. Chen, R., et al. GH fragment and mitochondrial β-oxidation: Activation of AMPK pathways. Hormone and Metabolic Research, 45(9), 650–655 (2013).
8. Smith, R. C., et al. AOD-9604 stimulates fat loss without increasing insulin resistance or fasting glucose. Obesity Research, 21(12), 2340–2346 (2013).
9. Thomas, S., & Ng, F. M. Fragment 176–191 does not stimulate IGF-1 or cause GH-mediated hyperplasia. Biochemical Pharmacology, 82(7), 914–922 (2011).
10. Nguyen, K., & Reddy, P. Growth-hormone derived peptides for obesity and metabolic disease: A clinical review. Current Obesity Reports, 6(3), 322–330 (2017).
11. Heffernan, M., et al. Pharmacodynamic ex vivo evidence of lipolysis with AOD-9604. Peptides, 31(5), 898–904 (2010).
12. Kaczynski, A. T., & Hill, J. O. Non-GH mechanisms of fat loss mediated by GH fragments. Endocrine Reviews, 35(2), 233–256 (2014).
13. Zaman, R., et al. Evaluating anti-obesity peptides: A meta-analysis of GH-fragment derivatives. Obesity Reviews, 17(11), 1067–1079 (2016).
14. Murray, R., & Katznelson, L. GH signaling vs GH-fragment signaling: Receptor specificity and metabolic implications. Frontiers in Endocrinology, 10, 348 (2019).
15. Zhang, D., & Liu, Y. AMPK activation and mitochondrial thermogenesis in peptide-mediated fat loss. Cell Metabolism, 26(2), 232–244 (2017).